Fusion Genes and RNAs in Cancer Development

Taniue, Kenzui; Akimitsu, Nobuyoshi

doi:10.3390/ncrna7010010

Cited by 32 publications

(48 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chimeric RNAs are evidently involved in cancer [17,18,87,88]. In cancer cells, chimeric RNAs could either produce oncogenic chimeric protein or oncogenic lncRNA, impacting cancer evolution and heterogeneity [25,64,86,[89][90][91].…”

Section: How Could Chimeric Rnas Lead To Cancer Evolution?mentioning

confidence: 99%

Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells

Mukherjee

Heng

Frenkel‐Morgenstern

2021

Cancers

View full text Add to dashboard Cite

Gene fusions can give rise to somatic alterations in cancers. Fusion genes have the potential to create chimeric RNAs, which can generate the phenotypic diversity of cancer cells, and could be associated with novel molecular functions related to cancer cell survival and proliferation. The expression of chimeric RNAs in cancer cells might impact diverse cancer-related functions, including loss of apoptosis and cancer cell plasticity, and promote oncogenesis. Due to their recurrence in cancers and functional association with oncogenic processes, chimeric RNAs are considered biomarkers for cancer diagnosis. Several recent studies demonstrated that chimeric RNAs could lead to the generation of new functionality for the resistance of cancer cells against drug therapy. Therefore, targeting chimeric RNAs in drug resistance cancer could be useful for developing precision medicine. So, understanding the functional impact of chimeric RNAs in cancer cells from an evolutionary perspective will be helpful to elucidate cancer evolution, which could provide a new insight to design more effective therapies for cancer patients in a personalized manner.

show abstract

Section: How Could Chimeric Rnas Lead To Cancer Evolution?mentioning

confidence: 99%

Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells

Mukherjee

Heng

Frenkel‐Morgenstern

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Recent studies identified several chimeric RNAs in different cancers that are associated with oncogenesis, cancer heterogeneity, and the evolution of cancer drug resistance [ 8 , 43 ]. The appearance of chimeric RNAs in a particular cell can promote functional expansion and increase phenotypic diversity to help the cell to survive in the face of new stresses.…”

Section: Discussionmentioning

confidence: 99%

The Landscape of Novel Expressed Chimeric RNAs in Rheumatoid Arthritis

Detroja

Mukherjee

Frenkel‐Morgenstern

2022

Cells

View full text Add to dashboard Cite

In cancers and other complex diseases, the fusion of two genes can lead to the production of chimeric RNAs, which are associated with disease development. Several recurrent chimeric RNAs are expressed in different cancers and are thus used for clinical cancer diagnosis. Rheumatoid arthritis (RA) is an immune-mediated joint disorder resulting in synovial inflammation and joint destruction. Despite advances in therapy, many patients do not respond to treatment and present persistent inflammation. Understanding the landscape of chimeric RNA expression in RA patients could provide a better insight into RA pathogenesis, which might provide better treatment strategies and tailored therapies. Accordingly, we analyzed the publicly available RNA-seq data of synovium tissue from 151 RA patients and 28 healthy controls and were able to identify 37 recurrent chimeric RNAs found to be expressed in at least 3 RA samples. Furthermore, the parental genes of these 37 recurrent chimeric RNAs were found to be differentially expressed and enriched in immune-related processes, such as adaptive immune response and the positive regulation of B-cell activation. Interestingly, the appearance of 5 coding and 23 non-coding chimeric RNAs might be associated with regulating their parental gene expression, leading to the generation of dysfunctional immune responses, such as inflammation and bone destruction. Therefore, in this paper, we present the first study to demonstrate the novel chimeric RNAs that are highly expressed and functional in RA.

show abstract

“…Fusion genes have been considered to play a role in driving tumor initiation, metastasis, and resistance to therapy in solid cancers as well as in hematological malignancies [ 19 , 20 ]. A number of genes, including kinases, transcription factors, and cell cycle regulators, generate fusion genes in many types of cancers, and the resulting structural alteration and different regulation can cause tumorigenesis and progression.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells

Nagasawa

Ikeda

Shintani

et al. 2022

IJMS

View full text Add to dashboard Cite

Gene structure alterations, such as chromosomal rearrangements that develop fusion genes, often contribute to tumorigenesis. It has been shown that the fusion genes identified in public RNA-sequencing datasets are mainly derived from intrachromosomal rearrangements. In this study, we explored fusion transcripts in clinical ovarian cancer specimens based on our RNA-sequencing data. We successfully identified an in-frame fusion transcript SPON1-TRIM29 in chromosome 11 from a recurrent tumor specimen of high-grade serous carcinoma (HGSC), which was not detected in the corresponding primary carcinoma, and validated the expression of the identical fusion transcript in another tumor from a distinct HGSC patient. Ovarian cancer A2780 cells stably expressing SPON1-TRIM29 exhibited an increase in cell growth, whereas a decrease in apoptosis was observed, even in the presence of anticancer drugs. The siRNA-mediated silencing of SPON1-TRIM29 fusion transcript substantially impaired the enhanced growth of A2780 cells expressing the chimeric gene treated with anticancer drugs. Moreover, a subcutaneous xenograft model using athymic mice indicated that SPON1-TRIM29-expressing A2780 cells rapidly generated tumors in vivo compared to control cells, whose growth was significantly repressed by the fusion-specific siRNA administration. Overall, the SPON1-TRIM29 fusion gene could be involved in carcinogenesis and chemotherapy resistance in ovarian cancer, and offers potential use as a diagnostic and therapeutic target for the disease with the fusion transcript.

show abstract

Fusion Genes and RNAs in Cancer Development

Cited by 32 publications

References 147 publications

Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells

Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells

The Landscape of Novel Expressed Chimeric RNAs in Rheumatoid Arthritis

Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells

Contact Info

Product

Resources

About